UCB raises 2026 revenue and adjusted EBITDA growth guidance on Bimzelx demand
On October 22, 2026, UCB raised its 2026 revenue-growth guidance to the low-twenties percentage range at constant exchange rates from the prior low- to mid-teens range. It also raised adjusted EBITDA-growth guidance to the low- to mid-forties range from the prior mid-teens to low-twenties range. UCB attributed the upgrade primarily to strong U.S. Bimzelx demand and favorable pricing trends, while also citing continued Cimzia contribution; the guidance excludes potential proceeds from a Priority Review Voucher sale.
This is a valid forward-looking business-performance development because UCB materially raised its 2026 revenue and adjusted EBITDA growth expectations; the source’s share-price commentary is excluded. The supplied context explicitly supports the guidance ranges and attributes the change primarily to stronger U.S. Bimzelx demand, patient conversion, retention, and pricing. UCB.BR is the direct and clearly supported stakeholder. NVS and LLY are approved as the most directly exposed IL-17 competitors, while the other listed companies and payers are too indirect or weakly supported for conservative approval. The announcement date is explicit, but the actual announcement time is not; the timestamp is therefore normalized to the start of October 22, 2026 UTC with reduced timestamp confidence.
The company now anticipates 2026 revenue growth in the low-twenties percentage range when excluding currency changes, up from its previous forecast of an increase in the low- to mid-teens range.
It also expects adjusted earnings before interest, taxes, depreciation and amortization growth to be in the low- to mid-forties at constant currency, which compares with the mid-teens to low-twenties range it previously guided for.
Strong U.S. sales for immunology drug Bimzelx due to robust patient demand and